SCHEMBL6746218

SCHEMBL6746218

CC1(C)OC[C@@H](C[C@@H](SC(=O)c2ccccc2)c2ccccc2)N1C(=O)O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 4/20 0.33
CYP1A2 P05177 2/20 0.33
TSHR P16473 2/20 0.33
NFKB1 P19838 1/20 0.33
LMNA P02545 1/20 0.33
CHRNB2 P17787 1/20 0.33
HTR2A P28223 1/20 0.33
HRH1 P35367 1/20 0.33
CHRNA7 P36544 1/20 0.33
CHRNA4 P43681 1/20 0.33
SLC18A2 Q05940 1/20 0.33
GPR139 Q6DWJ6 1/20 0.32
ALDH1A1 P00352 4/20 0.32
GLA P06280 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
KDM4C Q9H3R0 1/20 0.32
POLB P06746 1/20 0.32
MTNR1A P48039 1/20 0.32
MTNR1B P49286 1/20 0.32
CYP3A4 P08684 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4595234 1.00 CYP2D6 (0.33) CYP2D6CYP1A2TSHRNFKB1LMNA
SCHEMBL6746223 1.00 CYP2D6 (0.33) CYP2D6CYP1A2TSHRNFKB1LMNA
SCHEMBL6232927 1.00 CYP2D6 (0.33) CYP2D6CYP1A2TSHRNFKB1LMNA
SCHEMBL6752549 0.90 ITGB3 (0.37) CYP2C19
SCHEMBL6750156 0.87 KDM4E (0.37)
SCHEMBL6750153 0.87 KDM4E (0.37)
SCHEMBL5758333 0.84 P2RX7 (0.33)
SCHEMBL6750028 0.81 LMNA (0.31) LMNAALDH1A1HTT
SCHEMBL6750031 0.81 LMNA (0.31) LMNAALDH1A1HTT
SCHEMBL4595038 0.80 CYP2D6 (0.49) CYP2D6CYP1A2TSHRNFKB1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040242871-A1 Novel arylheteroalkylamine derivatives ASTRAZENECA AB (SE) 2004-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242871-A1 Novel arylheteroalkylamine derivatives CYP1A1, NOS3, NOS1 CYP2D6 48/4885CYP1A2 11/4885TSHR 1019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.